Study of the Release Kinetic and the Diffusion Coefficient of Doxorubicin-Chrysin Coated with Fe3O4 and Polycaprolactone-Polyethylene glycol Copolymers

Document Type : Research Article

Authors

1 Department of Chemical Engineering, Ahar Branch, Islamic Azad University, Ahar, I. R. IRAN

2 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, I.R. IRAN

Abstract

Abstract

Recent advances in the development of the magnetic nanoparticles modified with biodegradable polymers have shown promise in the improvement of therapeutic approaches for the clinical management of cancer patients. In this study, polycaprolactone -polyethylene glycol –polycaprolactone (PCL-PEG-PCL) copolymers modified with magnetic nanoparticles were used for encapsulation of doxorubicin (DOX) and chrysin (Chr) anticancer drugs by dual emulsion (W / O / W). The effect of temperature and pH on drug release was investigated. The release of the doxorubicin drug in pH 7.4 and 5.8 were 26.5% and 30.6%, respectively after 144 h. In chrysin drug, the release of drug in pH 7.4 and 5.8 was equal to 45% and 49%, respectively after 144 h. The kinetics of the drug's release was also studied based on zero-order, first-order, Higuchi, and Korsmeyer-Peppas models. From the kinetic models, based on the correlation coefficient, Higuchi (R2=0.9017) and Korsmeyer-Peppas (R2=0.9639) models were found to be the best models for doxorubicin and chrysin, respectively. After performing kinetic studies, the diffusion coefficient of drug release was also studied. The drug distribution was considered uniform, and the system was investigated in Cartesian and spherical coordinates. The results showed that the diffusion coefficient of drug release followed Fick's law. The diffusion coefficient decreased with increasing time due to decreasing the concentration difference.

Keywords

Main Subjects

References

[1] Kopecek J., Smart and Genetically Engineered Biomaterials and Drug Delivery Systems, Eur. J. Pharm. Sci, 20: 1-16 (2003).
[2] Salehpour P., Yegani R., Hajmohammadi R., Determination of Optimal Operation Conditions for Production of Cephalosporin G from Penicillin G Potassium, Org. Process Res. Dev., 16: 1507-1512 (2012).
[3] Fan Q.L., Neoh K.G., Kang E.T., Shuter B., Wang S.C., Solvent-Free Atom Transfers Radical Polymerization for the Preparation of Poly(Poly(Ethyleneglycol) Monomethacrylate)-Grafted Fe3O4 Nanoparticles: Synthesis, Characterization and Cellular Uptake, Biomaterials, 28: 5426-5436 (2007).
[4] Lombardo D., Kiselev M.A., Caccamo M.T., Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine, J. Nanomater. 1-26 (2018).
[5] Byrne J.D., Betancourt T., Brannon-Peppas L., Active Targeting Schemes for Nanoparticle Systems in Cancer Therapeutics, Adv. Drug Delivery Rev, 60: 15 1615-1626 (2008).
[6] Kumari P., Ghosh B., Biswas S., Nanocarriers for Cancer-Targeted Drug Delivery, J. Drug Target, 24(3):179-91 (2016).
[7] Peppas L.B., Blanchette J.O., Nanoparticle and Targeted Systems for Cancer Therapy, Adv. Drug. Delivery Rev., 56:1649-1659 (2004).
[8] Batrakova E.V., Gendelman H.E., Kabanov A.V., Cell-Mediated Drug Delivery, Expert Opin. Drug. Deliv., 8(4): 415-33 (2011).
[9] McNeeley K.M., Karathanasis E., Annapragada A.V., Bellamkonda R.V., Masking and Triggered Unmasking of Targeting Ligands on Nanocarriers to Improve Drug Delivery to Brain Tumors, Biomaterials, 30: 3986-3995 (2009).
[10] Andreeßen C., Steinbüchel A., Recent Developments in Non-Biodegradable Biopolymers: Precursors, Production Processes, and Future Perspectives, Advances in Environmental Microbiology, 103: 143-157 (2019).
[11] Banerjee D., Sengupta S., “Progress in Molecular Biology and Translational Science”. Elsevier Inc, 104: 489-507 (2011).
[12] Veiseh O., Gunn J W., Zhang M., Design and Fabrication of Magnetic Nanoparticles for Targeted Drug Delivery and Imaging, Adv. Drug. Delivery Rev., 62(3): 284-304 (2010).
[13] Ebadi M., Buskaran K., Bullo S., Zobir Hussein M., Fakurazi S., Pastorin G., Drug Delivery System Based on Magnetic Iron Oxide Nanoparticles Coated with (Polyvinyl Alcohol-Zinc/ Aluminium-Layered Double Hydroxide-Sorafenib), Alexandria Eng. J., 60: 733-747 (2021).
[14] Vakilinezhad M.A., Amini A., Dara. T., Alipour S., Methotrexate and Curcumin Co-encapsulated PLGA Nanoparticles as a Potential Breast Cancer Therapeutic System: In Vitro and In Vivo Evaluation. Colloids Surf., B. 184 (2019).   
[15] Heredia N., Vizuete K., Flores-Calero M., Pazmino V.K., Pilaquinga F., Kumar B., Debut A., Comparative Statistical Analysis of the Release Kinetics Models for Nanoprecipitated Drug Delivery Systems Based on Poly(Lactic-Coglycolic Acid), PLOS ONE, 17(3) (2022).
[16] Kumskova N., Ermolenko Y., Osipova N., Semyonkin A., Kildeeva N., Gorshkova M., Kovalskii A., Kovshova T., Tarasov V., Kreuter J., Maksimenko O., Gelperina S., How Subtle Differences in Polymer Molecular Weight Affect Doxorubicin-Loaded PLGA Nanoparticles Degradation and Drug Release, J. Microencapsul, 37: 283-295 (2020).
[17] Lagreca E., Onesto V., Di Natale C., La Manna S., Netti P.A., Vecchione R., Recent Advances in the Formulation of PLGA Microparticles for Controlled Drug Delivery, Prog. Biomater., 9: 153-174 (2020).
[18] Pourtalebi Jahromi L., Ghazali M., Ashrafi H., Azadi A., A Comparison of Models for the Analysis of the Kinetics of Drug Release from PLGA-Based Nanoparticles. Heliyon, 6(2): (2020).
[19] Horvath J., Maass K., Hieb A., Ranade S., Drug Release Kinetics of the Port Delivery System with Ranibizumab (PDS): Platform Technology for Continuous Retinal Drug Delivery, Invest. Ophthalmol. Visual Sci, 63: 7 (2022)
[20] Awasthi S., Singhal S.S., Singhal J., Cheng J., Zimniak P., Awasthi Y.C., Role of RLIP76 in Lung Cancer Doxorubicin Resistance: II. Doxorubicin Transport in Lung Cancer by RLIP76, Int. J. Oncol., 22(4): 713-720 (2003).
[21] Calcagno A.M., Fostel J.M., To K.K.W., Salcido C.D., Martin S.E., Chewning K.J.,  Wu C-P., Varticovski L., Bates S.E., Caplen N.J., Ambudkar S.V., Single-Step Doxorubicin-Selected Cancer Cells Overexpress the ABCG2 Drug Transporter through Epigenetic Changes, Br. J. Cancer, 98: 1515-1524 (2008).
[22] Kwon Y., Kim H., Park S., Jung S., Enhancement of Solubility and Antioxidant Activity of Some Flavonoids Based on the Inclusion Complexation with Sulfobutylether β-cyclodextrin, Bull. Korean Chem. Soc., 31(10): 3035-3037 (2010).
[23] Shahabi J., Akbarzadeh A., Heydarinasab A., Ardjmand M., Doxorubicin Loaded Liposomal Nanoparticles Containing Quantum Dot for Treatment of Breast Cancer, Iran. J. Chem. Chem. Eng. (IJCCE), 38(5): 45-53 (2019).
[24] Zeng J., Du P., Liu L., Li J., Tian K., Jia X., Superparamagnetic Reduction/pH/Temperature Multistimuli-Responsive Nanoparticles for Targeted and Controlled Antitumor Drug Delivery, Mol. Pharmaceutics,12: 4188-4199 (2015).
[25] Foroughi M.M., Jahani S., Aramesh-Boroujeni Z., Vakili Fathabadi M., Hashemipour Rafsanjani H., Rostaminasab Dolatabad M., Template-Free Synthesis of ZnO/Fe3O4/Carbon Magnetic Nanocomposite: Nanotubes with Hexagonal Cross Sections and Their Electrocatalytic Property for Simultaneous Determination of Oxymorphone and Heroin, Microchem. J., 17 (2021).
[26] Vakili Fathabadi M., Hashemipour Rafsanjani H., Foroughi M.M., Jahani Sh., Arefi Nia N., Synthesis of Magnetic Ordered Mesoporous Carbons (OMC) as an Electrochemical Platform for Ultrasensitive and Simultaneous Detection of Thebaine and Papaverine, J. Electrochem. Soc., 167: 2 (2020).
[27] Nikzamir N., Khojasteh H., Nobakht Vakili M., Azimi Ch., Ghanbari E., Preparation of Degeredable Polyprolactone Polymer (PCL)/Magnetic nanocomposite for Drug Delivery Systems Against Anticancer Compounds, J. Nanostruct, 11(3): 456-469 (2021).
[28] Jahangiri S., Amirkhani L., Akbarzadeh A., Hajimohammadi R., Encapsulation of Doxorubicin and Chrysin on Magnetic PCLPEG-PCL Nanoparticles: Optimization of Parameters and Drug Delivery Evaluation, Int. J. Nano Dimens., 12(4):380-392 (2021).
[29] Liang Y., Xiaoheng Fu X., Du C.H., Haoran X.H.,  Lai Y., Sun Y., Enzyme/pH-Triggered Anticancer Drug Delivery of Chondroitin Sulfate Modified Doxorubicin Nanocrystal, Artif. Cells Nanomed. Biotechnol., 48 (1): (2020).
[30] Deldar Y., Pilehvar-Soltanahmadi Y., Dadashpour M., Montazer Saheb S., Rahmati-Yamchi M., Zarghami N., An In Vitro Examination of the Antioxidant, Cytoprotective and Anti-Inflammatory Properties of Chrysin-Loaded Nanofibrous Mats for Potential Wound Healing Applications, Artif. Cells Nanomed. Biotechnol., 46: 706-716 (2018).
[31] Dash S., Murthy P.N., Nath L., Chowdhury P., Kinetic Modeling on Drug Release from Controlled Drug Delivery Systems, Acta Pol Pharm., 67: 217-223 (2016).
[32] Korsmeyer R.W., Gurny R., Doelker E., Buri P., Peppas N.A., Mechanisms of Solute Release from Porous Hydrophilic Polymers, Int. J. Pharm., 15: 25-35 (1983).
[33] Baker R., Wiley J., Controlled Release of Biologically Active Agents, J. Pharm. Sci., 77 (1987).
[34] Siepmann, J., Siepmann. F., Modeling of Diffusion Controlled Drug Delivery, J. Controlled Release, 161: 351-362 (2012).
[35] Ritger P.L., Peppas N.A., A Simple Equation for Description of Solute Release I. Fickian and Non-Fickian Release from Non-Swellable Devices in the Form of Slabs, Spheres, Cylinders or Discs, J. Controlled Release, 5(1): 23-36 (1987).

Files

Share

How to cite

Statistics